Becomes the first subcutaneously administered PD-1 inhibitor.

Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.

Novo Nordisk will soon acquire from Novo Holdings Catalent’s three fill-finish sites located in Italy, the U.S., and Belgium.

Will support clinical development of Nirsum’s lead development candidate, NRS-033.

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients ...

Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Partnership leverages PHICS technology to bring together a kinase and target of interest to modulate protein function.

The expanded facility will focus on manufacturing injectable medicines, device assembly and packaging for medicines across ...

Charles Sternberg is a driven writer and editor with a well developed passion for creativity and innovation seeking to ...

LGM Pharma’s chief executive talks industry trends and the company’s continued growth as a provider of tailored API and CDMO services. Contract Pharma is the premier media outlet linking contract ...